Stay updated on Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Sign up to get notified when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.

Latest updates to the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a Locations section with a Texas site; removed the Texas Locations section and the HHS Vulnerability Disclosure link, and updated the revision to v3.3.3.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check44 days agoChange DetectedAn editorial note was added that publications are automatically filled from PubMed, and the page revision was updated to v3.3.2. The previous wording about PubMed publications and automatic listing by ClinicalTrials.gov was removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedThe government funding/operation status notice has been removed from the page, leaving the focus on the study details and related information.SummaryDifference0.3%

- Check65 days agoChange DetectedNo significant changes were detected. The Study Details page remains the same in content and layout.SummaryDifference0.3%

- Check94 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%

- Check101 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.